Company intelligence
BLS Pharmaceuticals Limited
A NOVEL APPROACH TO HEALTHCARE, EXTRAORDINARY RESULTS
About BLS Pharmaceuticals Limited
BLS Pharmaceuticals Limited (ASX:BLS) is an Australian pharmaceutical company focused on the manufacture, development and commercialisation of regulated therapeutic products and active pharmaceutical ingredients. Through its wholly owned subsidiary, Breathe Life Sciences, the Company operates a GMP-licensed manufacturing, import, export and distribution platform spanning medicinal cannabis, psychedelic medicines and other controlled pharmaceutical products. BLS maintains operations across Australia, Europe, the United Kingdom and Japan, supplying pharmaceutical products and manufacturing services to regulated international markets through a growing network of commercial partners. In 2023 BLS was acquired by Bioxyne (BXN:ASX) and more recently, in June 2026, changed its name from Bioxyne Limited to BLS Pharmaceuticals Limited. A new era. A new name. Same vision. To redefine medicine.
Verified activity
Signals from BLS Pharmaceuticals Limited
12 published signals
Capital & Finance
BLS Pharmaceuticals Limited was added to the All Ordinaries Index effective prior to market open on 21 September 2026 following the September quarterly review by S&P Dow Jones Indices.
Reported by BLS Pharmaceuticals Limited
Presence & Recognition
BLS Pharmaceuticals Limited hosted an investor webinar featuring CEO and Managing Director Sam Watson discussing FY2026 Full Year Results, FY27 outlook, and growth strategy.
Reported by BLS Pharmaceuticals Limited
Capital & Finance
BLS Pharmaceuticals Limited transformed from an Australian micro-cap business into a small-cap international pharmaceutical platform in FY26.
Reported by BLS Pharmaceuticals Limited